Proteostasis Therapeutics to Present at Upcoming Investor Conferences
September 15 2016 - 6:30PM
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical
company developing small molecule therapeutics to treat diseases
caused by dysfunctional protein processing such as cystic fibrosis
(CF), today announced that Meenu Chhabra, president and chief
executive officer of Proteostasis Therapeutics, will present at the
following upcoming investor conferences:
- Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Series on Wednesday, September 28, 2016 at 2:05 p.m. ET in New York
City.
- Jefferies Cystic Fibrosis Summit on Thursday, September 29,
2016 at 8:45 a.m. ET in New York City.
A live audio webcast of the Leerink Partners presentation will
be available on the Event Calendar page in the Investors &
Media section of the Company’s website, www.proteostasis.com. A
replay of the webcast will be available on the Company’s website
following the presentation.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a biopharmaceutical company
dedicated to the discovery of groundbreaking therapies to treat
diseases caused by dysfunctional protein processing, such as cystic
fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis
Therapeutics team focuses on identifying therapies that modulate
the proteostasis imbalance in cells and restore protein function.
Proteostasis Therapeutics is currently enrolling eligible adults
with CF to participate in its Phase 1 clinical trials of PTI-428.
PTI-428 is a unique modulator of the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) protein, called an amplifier, that
when used in combination with existing treatments and therapies has
shown a consistent positive effect on CFTR protein activity in
vitro in pre-clinical studies. In addition to its multiple programs
in cystic fibrosis, Proteostasis Therapeutics has formed
collaborations with Biogen to research and identify therapeutic
candidates for neurodegenerative disease and with Astellas Pharma,
Inc. to research and identify therapies targeting the Unfolded
Protein Response (UPR) pathway. For more information, visit
www.proteostasis.com.
Media Contact:
Katie Engleman, Pure Communications, Inc.
(910) 509-3977
katie@purecommunicationsinc.com
Investor Contact:
Luke Heagle, Pure Communications, Inc.
(910) 726-1372
luke@purecommunicationsinc.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024